Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, September 20, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 19, 2019, Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 13,500 Ordinary Shares at a price of GBP0.59 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Denise Scots-Knight |
2 |
Reason for the notification |
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
GBP0.59 |
13,500 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 13,500 Aggregated price: GBP0.59 |
e) |
Date of the transaction |
2019-09-19 |
f) |
Place of the transaction |
AIMX |